|
Experience and Background
James A. Lebovitz represents corporate clients, including private and public healthcare, technology, and growth companies, as well as venture capital investors and investment banking firms in corporate finance transactions, mergers and acquisitions, and general corporate matters.
Mr. Lebovitz has been recognized as a leading lawyer for corporate/M&A and private equity by Chambers USA, a referral guide to leading lawyers in the United States, which reports that "he knows just how to get the deal done." Mr. Lebovitz is also recognized as a leading lawyer for corporate law, securities law, mergers and acquisitions law, leveraged buyouts and private equity law, and biotechnology law in The Best Lawyers in America and is listed for his extensive corporate finance experience in The Legal 500 (U.S.), which praises him for his "unique combination of nuts and bolts wisdom, as well as experienced counsel in complicated matters."
Mr. Lebovitz is recognized for his ability to capture and structure the capital healthcare companies need, including private placements and public offerings, and to support the long development and commercialization process. He also negotiates and executes strategic mergers, acquisitions, divestitures, spin-offs, joint ventures, and other strategic collaborations to enhance the development and commercialization of new technologies and scientific breakthroughs. In addition, Mr. Lebovitz has experience advising companies in the technology, real estate, and business and financial services industries.
Mr. Lebovitz is the chair of Dechert's firm-wide lawyer hiring committee and previously served as partner responsible for associate development. From 2000 to 2005, he served as chair of the firm's business and technology practice group.
Mr. Lebovitz joined Dechert in July 1999 as a partner in the Philadelphia office following three years as the general counsel of a national, publicly traded, physician practice management company.
Professional Activities
Mr. Lebovitz is a trustee of Choate Rosemary Hall and a director of The Mann Center for the Performing Arts. Mr. Lebovitz is a former trustee of the Philadelphia Museum of Art and of The Baldwin School and is a past president and current member of the Board of Trustees of the Samuel S. Fleisher Art Memorial.
Significant Representations
In the last few years alone, Mr. Lebovitz has advised on a wide range of domestic and international corporate finance and M&A transactions, including:
-- J.P. Morgan in its role as: underwriter in the $86 million initial public offering of Emergent BioSolutions Inc. and the $57.1 million primary offering by Savient Pharmaceuticals, Inc.; initial purchaser in the $125 million offering of convertible notes and common stock by Oscient Pharmaceuticals Corporation; and placement agent in the $88 million public offering by Genome Therapeutics, $40 million offering by Altair Nanotechnologies, $31.9 million registered direct offering by Barrier Therapeutics, Inc., $30 million public offering by ArQule, Inc., $33.8 and $23.9 million public offerings by Neose Technologies, and $27.6 million offering by Bioenvision, Inc.
-- Covance Inc., a leading clinical research organization (CRO) providing drug development services, in its $1.6 billion ten-year strategic alliance with Eli Lilly and Company and its acquisition of the Gene Expression Laboratory from Merck
-- Florida Health Plan Administrators, LLC, the owner of Vista Healthplans, a private, Florida-based diversified health plan serving approximately 295,000 members, in its $685 million sale to Coventry Health Care
-- Cephalon, Inc. in its $450 million acquisition of France-based Group Lafon, its $160 million acquisition of the outstanding capital stock of Salmedix, Inc., and its co-promotion agreements with McNeil Consumer & Specialty Pharmaceuticals and Takeda Pharmaceuticals North America
-- HFF, Inc. in its $257 million initial public offering of Class A common stock
-- MWI Veterinary Supply, Inc. in its $73.6 million initial public offering and $93.6 million follow-on offering of common stock
-- Cowen and Company as placement agent in the $31.9 million PIPE by Iomai Corporation and as financial advisor to PhotoMedex, Inc. in its acquisition of Photo Therapeutics Limited
-- Adolor Corporation in its $140 million and $103.5 million follow-on offerings of common stock
Education
Yale College, B.A., 1979, Editor-in-chief of the Yale Daily News
University of Virginia School of Law, J.D., 1982, Notes editor of The Virginia Journal of International Law
University of Cambridge, LL.M., 1983
Publications and Lectures
|
